RecruitingNot applicableNCT06911632
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Studying Pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tempus AI
- Intervention
- ECG-based AI Device - Results Returned to Investigator(device)
- Enrollment
- 900 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (25)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner University Medical Center, Phoenix, Arizona, United States
- Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix, Arizona, United States
- National Jewish Health, Denver, Colorado, United States
- AdventHealth Orlando, Orlando, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Illinois Health, Chicago, Illinois, United States
- Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
- Community Health Network, Indianapolis, Indiana, United States
- University of Kentucky, Lexington, Kentucky, United States
- Louisiana State University Health Shreveport, Shreveport, Louisiana, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- University of Michigan - Michigan Medicine, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Hannibal Regional Healthcare System, Hannibal, Missouri, United States
- +10 more locations on ClinicalTrials.gov
Collaborators
United Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06911632 on ClinicalTrials.govOther trials for Pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07593027A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
- RECRUITINGNANCT07563322Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary HypertensionVanderbilt University Medical Center
- ACTIVE NOT RECRUITINGNANCT07391228Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)Alessandra Gorini
- RECRUITINGNANCT06871293Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19Fundación Cardioinfantil Instituto de Cardiología
- ACTIVE NOT RECRUITINGPHASE3NCT06274801Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)GB002, Inc.
- RECRUITINGPHASE2NCT05937854Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PHVA Office of Research and Development
- RECRUITINGNCT06291389Intraoperative Peak Airway Pressure Changes on Postoperative Pulmonary Function After Muscle PlicationAl-Azhar University
- ACTIVE NOT RECRUITINGNANCT07253363Circulating Activin-A and FSTL3 in Precapillary Pulmonary HypertensionAssistance Publique - Hôpitaux de Paris